GO
Loading...

FDA Panel Backs Provenge

Friday, 30 Mar 2007 | 6:30 AM ET

The FDA voted unanimously that Dendreon's cancer drug Provenge is reasonably safe and 13 to 4 that there's substantial evidence the drug is effective. Dendreon CEO Dr. Mitchell Gold discusses his company's outlook with CNBC's Mike Huckman.